氨氯地平改善慢性肾病犬的对称二甲基精氨酸。

IF 2.6 2区 农林科学 Q1 VETERINARY SCIENCES
Frontiers in Veterinary Science Pub Date : 2025-04-30 eCollection Date: 2025-01-01 DOI:10.3389/fvets.2025.1570349
Shohei Morita, Youhei Mochizuki, Takahiro Kondo, Yasuyoshi Matsuda, Takahiro Ohmori, Aritada Yoshimura, Ryuji Fukushima
{"title":"氨氯地平改善慢性肾病犬的对称二甲基精氨酸。","authors":"Shohei Morita, Youhei Mochizuki, Takahiro Kondo, Yasuyoshi Matsuda, Takahiro Ohmori, Aritada Yoshimura, Ryuji Fukushima","doi":"10.3389/fvets.2025.1570349","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.</p><p><strong>Methods: </strong>This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).</p><p><strong>Results: </strong>Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.</p><p><strong>Discussion: </strong>It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.</p>","PeriodicalId":12772,"journal":{"name":"Frontiers in Veterinary Science","volume":"12 ","pages":"1570349"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075874/pdf/","citationCount":"0","resultStr":"{\"title\":\"Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease.\",\"authors\":\"Shohei Morita, Youhei Mochizuki, Takahiro Kondo, Yasuyoshi Matsuda, Takahiro Ohmori, Aritada Yoshimura, Ryuji Fukushima\",\"doi\":\"10.3389/fvets.2025.1570349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.</p><p><strong>Methods: </strong>This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).</p><p><strong>Results: </strong>Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.</p><p><strong>Discussion: </strong>It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.</p>\",\"PeriodicalId\":12772,\"journal\":{\"name\":\"Frontiers in Veterinary Science\",\"volume\":\"12 \",\"pages\":\"1570349\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075874/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Veterinary Science\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.3389/fvets.2025.1570349\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Veterinary Science","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fvets.2025.1570349","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

在犬类中,慢性肾脏疾病(CKD)经常与高血压相关。氨氯地平用于治疗狗的高血压,我们预计氨氯地平可以改善狗的肾功能。然而,氨氯地平对犬肾功能的影响尚不清楚。因此,本研究评估了对称二甲基精氨酸(SDMA)水平在氨氯地平给药前后的变化,这些宠物狗被诊断为CKD,基于SDMA水平持续升高,并且出于任何原因单独使用氨氯地平治疗。我们还进行了一项比较调查,看看这些CKD狗是否患有高血压,SDMA的变化是否有任何差异。方法:本研究采用回顾性设计。研究对象为SDMA持续升高(≥14 μg/dL)、诊断为CKD并给予氨氯地平治疗的宠物犬。收集犬种、性别、年龄等资料,以及使用氨氯地平前后的血液化学检查、血压、心率、超声心动图等资料。研究共纳入45只狗,其中高血压(HT:收缩压≥160 mmHg) 20只,非高血压(Non-HT:收缩压)25只。结果:HT组和非HT组给药后平均SDMA均较给药前显著降低。此外,我们发现所有接受氨氯地平治疗的CKD犬的心输出量(CO)都增加了。血压测量显示,HT组和非HT组的血压都有所下降。讨论:我们认为氨氯地平引起的CO升高增加了肾小球滤过率,这可能导致SDMA水平降低。基于收缩压降低的速率,我们认为氨氯地平可能在高血压水平较高的患者中降低血压的量更大。在这项研究中,我们发现氨氯地平可以改善CKD犬的SDMA,无论它们是否患有高血压。我们还表明氨氯地平可以安全地用于治疗正常血压的狗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease.

Introduction: In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.

Methods: This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).

Results: Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.

Discussion: It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Frontiers in Veterinary Science
Frontiers in Veterinary Science Veterinary-General Veterinary
CiteScore
4.80
自引率
9.40%
发文量
1870
审稿时长
14 weeks
期刊介绍: Frontiers in Veterinary Science is a global, peer-reviewed, Open Access journal that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy. Veterinary research today is interdisciplinary, collaborative, and socially relevant, transforming how we understand and investigate animal health and disease. Fundamental research in emerging infectious diseases, predictive genomics, stem cell therapy, and translational modelling is grounded within the integrative social context of public and environmental health, wildlife conservation, novel biomarkers, societal well-being, and cutting-edge clinical practice and specialization. Frontiers in Veterinary Science brings a 21st-century approach—networked, collaborative, and Open Access—to communicate this progress and innovation to both the specialist and to the wider audience of readers in the field. Frontiers in Veterinary Science publishes articles on outstanding discoveries across a wide spectrum of translational, foundational, and clinical research. The journal''s mission is to bring all relevant veterinary sciences together on a single platform with the goal of improving animal and human health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信